Radiometal complexes: characterization and relevant in vitro studies

Simple item page
dc.contributor.authorJurisson, Sen_AU
dc.contributor.authorCutler, CSen_AU
dc.contributor.authorSmith, SVen_AU
dc.date.accessioned2010-10-19T23:35:58Zen_AU
dc.date.available2010-10-19T23:35:58Zen_AU
dc.date.issued2007-05-01en_AU
dc.date.statistics2008-09en_AU
dc.description.abstractRadiometals are, and will continue to be, very important to diagnostic and therapeutic nuclear medicine applications as they predominantly possess the most suitable nuclear properties for these types of applications. This article attempts to give the reader an overview of key aspects that need to be considered in the design and synthesis of a radiopharmaceutical using the commonly known and employed radionuclides, such as technetium, rhenium, the lanthanides and copper. While it is important to understand each radiometal ion has its own specific coordination chemistry requirements, there are several issues that are critical to all radiometal ions for their incorporation into a radiopharmaceutical. 1) The route of production and the presence of long lived contaminating radionuclides and or of naturally occurring metal ions that will interfere with the efficient and optimum radiolabelling of their ligand of choice as well as the final specific activity of the product; 2) the significant differences between the chemistry at the macroscopic (mM and higher concentrations) and radiotracer levels (uM and lower concentrations for the high specific activity radionuclides); 3) the rate of complexation and of dissociation of the radiometal ion vs the competing reaction of radiometal hydrolysis; 4) natural biological pathway of the radio-metal ion and therefore the design of the appropriate and relevant in vitro tests to assess the stability of the radiometal complex. These are a selection of critical factors that need to be considered in the design of a successful radiopharmaceutical, whether it is used for imaging or therapy. However, one should consider tailoring their investigations to suit the radiometal under investigation, and to be mindful where the technology is to be applied (e.g. imaging organs or disease).en_AU
dc.identifier.citationJurisson, S., Cutler, C., & Smith, S. V. (2007). Radiometal complexes: characterization and relevant in vitro studies. Paper presented to the 17th International Symposium on Radiopharmaceutical Sciences - "Design of In Vitro and In Vivo Studies - Opportunities and Challenges" Workshop, 30th April - 4th May 2007. Eurogress: Aachen, Germany. In Quarterly Journal of Nuclear Medicine and Molecular Imaging, 52(3), 222-234.en_AU
dc.identifier.conferenceenddate4 May 2007en_AU
dc.identifier.conferencename17th International Symposium on Radiopharmaceutical Sciences - 'Design of In Vitro and In Vivo Studies - Opportunities and Challenges' Workshopen_AU
dc.identifier.conferenceplaceAachen, Germanyen_AU
dc.identifier.conferencestartdate30 April 2007en_AU
dc.identifier.govdoc2862en_AU
dc.identifier.issn1824-4661en_AU
dc.identifier.issue3en_AU
dc.identifier.journaltitleQuarterly Journal of Nuclear Medicine and Molecular Imagingen_AU
dc.identifier.pagination222-234en_AU
dc.identifier.urihttp://www.minervamedica.it/en/journals/nuclear-med-molecular-imaging/article.php?cod=R39Y2008N03A0222en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/2703en_AU
dc.identifier.volume52en_AU
dc.language.isoenen_AU
dc.publisherEdizioni Minerva Medicaen_AU
dc.subjectNuclear medicineen_AU
dc.subjectRadiopharmaceuticalsen_AU
dc.subjectIn vitroen_AU
dc.subjectIonsen_AU
dc.subjectRadioisotopesen_AU
dc.subjectComplexesen_AU
dc.titleRadiometal complexes: characterization and relevant in vitro studiesen_AU
dc.typeConference Paperen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Conference Publications